CN1303089C - 阿德福韦酯结晶形态及其制备方法 - Google Patents
阿德福韦酯结晶形态及其制备方法 Download PDFInfo
- Publication number
- CN1303089C CN1303089C CNB021487448A CN02148744A CN1303089C CN 1303089 C CN1303089 C CN 1303089C CN B021487448 A CNB021487448 A CN B021487448A CN 02148744 A CN02148744 A CN 02148744A CN 1303089 C CN1303089 C CN 1303089C
- Authority
- CN
- China
- Prior art keywords
- adefovir
- crystalline form
- adefovir dipivoxil
- adefovir ester
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 19
- 229960003205 adefovir dipivoxil Drugs 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 238000002425 crystallisation Methods 0.000 claims abstract description 19
- 230000008025 crystallization Effects 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 229960001997 adefovir Drugs 0.000 claims description 78
- -1 adefovir ester Chemical class 0.000 claims description 70
- 239000013078 crystal Substances 0.000 claims description 33
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 27
- 239000007787 solid Substances 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 238000001291 vacuum drying Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 4
- 229940011051 isopropyl acetate Drugs 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 3
- 229960001701 chloroform Drugs 0.000 claims description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 229910017488 Cu K Inorganic materials 0.000 claims 1
- 229910017541 Cu-K Inorganic materials 0.000 claims 1
- 230000003595 spectral effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 10
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 6
- 208000000419 Chronic Hepatitis B Diseases 0.000 abstract description 3
- 208000002672 hepatitis B Diseases 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- 229930024421 Adenine Natural products 0.000 abstract 1
- 229960000643 adenine Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000003756 stirring Methods 0.000 description 13
- 239000011782 vitamin Substances 0.000 description 11
- 235000013343 vitamin Nutrition 0.000 description 11
- 229940088594 vitamin Drugs 0.000 description 11
- 229930003231 vitamin Natural products 0.000 description 11
- 150000003722 vitamin derivatives Chemical class 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000004455 differential thermal analysis Methods 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 239000012535 impurity Substances 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- 238000005192 partition Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- MZSBWBNMVOPWIU-UHFFFAOYSA-N C(C)OP(OCC)(O)C.[O] Chemical compound C(C)OP(OCC)(O)C.[O] MZSBWBNMVOPWIU-UHFFFAOYSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 231100000460 acute oral toxicity Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- JGRXQQMGWYSNMI-UHFFFAOYSA-N C(C)OP(OCC)(O)C Chemical compound C(C)OP(OCC)(O)C JGRXQQMGWYSNMI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910003691 SiBr Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950007655 esilate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- OZNYZQOTXQSUJM-UHFFFAOYSA-N n,n'-dicyclohexylmorpholine-4-carboximidamide Chemical compound C1CCCCC1NC(N1CCOCC1)=NC1CCCCC1 OZNYZQOTXQSUJM-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
2θ | 晶面间距(d值) | I/I0 |
3.687.367.8410.1212.3614.8015.1616.3617.2818.0420.1620.4421.2822.2826.08 | 23.9912.0011.278.737.165.985.845.415.134.914.404.344.173.993.41 | 1002549811920143125149112710 |
溶剂 | 形态1(1g用量) | 新形态(1g用量) | 溶解度 |
甲醇 | 0.9ml | 0.95ml | 极易溶 |
二氯甲烷 | 2.9ml | 3.3ml | 易溶 |
0.1M HCL | 25.0ml | 30.0ml | 溶解 |
水 | 10000ml不溶 | 10000ml不溶 | 几乎不溶 |
pH | 分配系数 | |
形态1 | 新形态 | |
2458 | 1.4727.657.522.5 | 1.4126.655.721.9 |
放置条件 | 形态1 | 新形态 | |
60℃60℃光照光照75%湿度75%湿度 | 时间0天5天10天5天10天5天10天 | 杂质总量%0.360.390.480.340.340.390.40 | 杂质总量%0.840.940.980.851.020.860.95 |
pH4 | pH7 | pH8 | |
放置时间 | 总杂质量% | 总杂质量% | 总杂质量% |
形态1 新形态 | 形态1 新形态 | 形态1 新形态 | |
0hr | 0.41 1.20 | ||
2hr | 0.56 1.39 | 10.4 5.02 | 20.9 16.3 |
5hr | 1.78 1.60 | 9.19 6.96 | 31.5 28.2 |
8hr | 2.12 1.90 | 10.8 10.5 | 39.5 40.0 |
时间 | 给药后的平均经时血药浓度(ng/ml) | |||||||||
(min) | 10 | 30 | 45 | 60 | 90 | 120 | 180 | 240 | 360 | 480 |
新形态 | 1255.1±494.0 | 1726.3±346.4 | 1749.9±413.9 | 1442.0±463.4 | 1003.6±363.3 | 713.9±268.8 | 563.1±179.3 | 496.5±184.6 | 292.7±92.4 | 242.4±67.1 |
形态1 | 800.4±200.6 | 1806.3±677.0 | 1780.8±690.4 | 1582.0±648.3 | 966.5±413.9 | 611.3±208.4 | 598.8±254.6 | 442.1±146.0 | 402.8±308.1 | 247.4±98.6 |
药物 | Cmax(ng/ml) | AUC(0-Tn)(ng·hr/ml) | Tpeak(min) |
新形态 | 1783.8±359.4 | 4863.2±1332.3 | 45±9.5 |
形态1 | 1904.0±683.4 | 4955.0±1533.3 | 60±59.2 |
处方1 | 处方2 | 处方3 | 处方4 | |
阿德福韦酯 | 10mg | 10mg | 10mg | 10mg |
微晶纤维素 | 28mg | 28mg | 28mg | |
乳糖 | 44.67mg | 16mg | 30.6mg | 28.15mg |
预交化淀粉 | 3.33mg | |||
淀粉 | 15.15mg | |||
微粉硅胶 | 0.35mg | 0.2mg | 0.35mg | |
羟丙基纤维素 | 2.5mg | 2.8mg | ||
碳酸钙 | ||||
滑石粉 | 4mg | 0.5mg | ||
交联羧甲基纤维素钠 | 4mg | |||
硬脂酸镁 | 0.67mg | 0.7mg | 0.7mg | 0.7mg |
项目 | 5′ | 10′ | 20′ | 30′ | 45′ | 60′ |
溶出率(%) | 19.2 | 29.3 | 56.5 | 83.6 | 94.8 | 98.2 |
项目 | 020225批 | 020226批 | 020227批 | |||
高(cm) | 3.31 | 3.75 | 3.15 | 2.98 | 3.51 | 3.46 |
直径(cm) | 8.65 | 8.75 | 8.24 | 8.26 | 8.53 | 8.34 |
休止角 | 37.43 | 40.60 | 37.22 | 35.819 | 39.45 | 39.68 |
平均θ(度) | 39.02 | 36.52 | 39.57 | |||
38.37<45 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021487448A CN1303089C (zh) | 2002-11-19 | 2002-11-19 | 阿德福韦酯结晶形态及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021487448A CN1303089C (zh) | 2002-11-19 | 2002-11-19 | 阿德福韦酯结晶形态及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1435420A CN1435420A (zh) | 2003-08-13 |
CN1303089C true CN1303089C (zh) | 2007-03-07 |
Family
ID=27628726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021487448A Expired - Lifetime CN1303089C (zh) | 2002-11-19 | 2002-11-19 | 阿德福韦酯结晶形态及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1303089C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7417036B2 (en) * | 2002-11-12 | 2008-08-26 | Tianjin Kinsly Pharmaceutical Co. Ltd. | Crystal form of adefovir dipivoxil and its preparation |
CN100415756C (zh) * | 2003-10-14 | 2008-09-03 | 沈阳药科大学 | 草酸阿地福韦酯及其晶型和制备方法及用途 |
CN101085785B (zh) * | 2006-06-06 | 2011-09-21 | 中国科学院上海药物研究所 | 用于治疗乙型肝炎的嘌呤类化合物及其制备方法和用途,以及包括该化合物的组合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000016755A2 (en) * | 1998-09-18 | 2000-03-30 | Glaxo Group Limited | Antiviral combinations of lamivudine and adefovir |
CN1251592A (zh) * | 1997-07-25 | 2000-04-26 | 吉尔利德科学股份有限公司 | 核苷酸类似物组合物 |
WO2001091737A2 (en) * | 2000-05-26 | 2001-12-06 | Idenix (Cayman) Limited | Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
CN1396170A (zh) * | 2002-07-08 | 2003-02-12 | 江苏正大天晴药业股份有限公司 | 匹伏阿德福韦的晶型 |
CN1506371A (zh) * | 2002-11-12 | 2004-06-23 | 天津市金士力药物研究开发有限公司 | 一种新的晶状埃地双酯及其组合物 |
-
2002
- 2002-11-19 CN CNB021487448A patent/CN1303089C/zh not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1251592A (zh) * | 1997-07-25 | 2000-04-26 | 吉尔利德科学股份有限公司 | 核苷酸类似物组合物 |
WO2000016755A2 (en) * | 1998-09-18 | 2000-03-30 | Glaxo Group Limited | Antiviral combinations of lamivudine and adefovir |
WO2001091737A2 (en) * | 2000-05-26 | 2001-12-06 | Idenix (Cayman) Limited | Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
CN1396170A (zh) * | 2002-07-08 | 2003-02-12 | 江苏正大天晴药业股份有限公司 | 匹伏阿德福韦的晶型 |
CN1506371A (zh) * | 2002-11-12 | 2004-06-23 | 天津市金士力药物研究开发有限公司 | 一种新的晶状埃地双酯及其组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN1435420A (zh) | 2003-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018532732A (ja) | B型肝炎抗ウイルス薬の結晶形態 | |
CN1835951A (zh) | 选择性cdk4抑制剂的羟乙基磺酸盐 | |
WO2011095059A1 (zh) | 达沙替尼多晶型物及其制备方法和药物组合物 | |
CN1426418A (zh) | 膦酸酯核苷酸化合物 | |
CN1867564A (zh) | 氨基巴豆基化合物的制备方法 | |
CN1861604A (zh) | 阿色纳品马来酸盐的晶型 | |
CN1745755A (zh) | 含核苷酸类似物的组合物及其合成方法 | |
CN1793132A (zh) | 环黄芪醇类衍生物以及用途 | |
CN1554350A (zh) | 含核苷酸类似物的组合物及其合成方法 | |
CN111205325A (zh) | 替诺福韦艾拉酚胺复合物及其制备方法和用途 | |
CN1623985A (zh) | 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 | |
CN1198799C (zh) | (s)-2-乙氧基-3-[4-(2-{4-甲磺酰氧基苯基}乙氧基)苯基]丙酸的晶形 | |
CN1612878A (zh) | 伐昔洛韦的合成与纯化 | |
CN1646490A (zh) | 新的阿托韦兹他汀半钙结晶以及制备它们的方法,以及新的制备阿托韦兹他汀半钙形式ⅰ,ⅷ和ⅸ的方法 | |
CN112142679A (zh) | 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法 | |
US20070060599A1 (en) | Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | |
CN1303089C (zh) | 阿德福韦酯结晶形态及其制备方法 | |
CN1031060C (zh) | 新颖酯类的制造方法 | |
CN1308307C (zh) | 假多晶型的卡维地洛 | |
CN1009826B (zh) | 制备喹啉基化合物的方法 | |
KR20060015750A (ko) | 지프라시돈 HCl의 다형 형태 및 그 제조 방법 | |
CN1501939A (zh) | 嘧啶核苷衍生物的晶体 | |
CN1498216A (zh) | 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法 | |
CN1503796A (zh) | 顺-ftc的多晶型物及其它晶型 | |
CN1712408A (zh) | 双环醇糖苷类化合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hainan kangllian Pharmaceutical Co.,Ltd.|TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH PHARMACEUTICAL RESPONSIBLE CO.,LTD. Assignor: Tianjin Institute of Pharmaceutical Research Contract fulfillment period: 2007.9.18 to 2022.11.18 Contract record no.: 2007990000100 Denomination of invention: Crystalline form of Adefovir dipivoxil and preparing process thereof Granted publication date: 20070307 License type: Exclusive license Record date: 20071220 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.9.18 TO 2022.11.18 Name of requester: HAINAN KANGLIAN PHARMACEUTICAL CO., LTD., TIANJIN Effective date: 20071220 |
|
EM01 | Change of recordation of patent licensing contract |
Change date: 20100402 Contract record no.: 2007990000100 Assignee after: SHANGHAI GUOCHUANG MEDICINE Co.,Ltd. Assignee after: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH PHARMACEUTICAL RESPONSIBLE CO.,LTD. Assignee before: Hainan kangllian Pharmaceutical Co.,Ltd. Assignee before: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH PHARMACEUTICAL RESPONSIBLE CO.,LTD. |
|
C35 | Partial or whole invalidation of patent or utility model | ||
IP01 | Partial invalidation of patent right |
Commission number: 4W02247 Conclusion of examination: On the basis of the claim 1-7 submitted by the patent holder in January 13, 2009, the patent rights of invention patent No. 2148744.8 shall be maintained, and the claim 1-7 shall be effective. Decision date of declaring invalidation: 20090831 Decision number of declaring invalidation: 13804 Denomination of invention: Crystalline form of Adefovir dipivoxil and preparing process thereof Granted publication date: 20070307 Patentee: Tianjin Institute of Pharmaceutical Research |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070307 |